Achmea Investment Management B.V. Cuts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Achmea Investment Management B.V. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 63.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,905 shares of the medical device company’s stock after selling 31,074 shares during the period. Achmea Investment Management B.V.’s holdings in DexCom were worth $1,393,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Jennison Associates LLC increased its holdings in DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. increased its holdings in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD purchased a new position in DexCom in the fourth quarter valued at about $96,507,000. Westfield Capital Management Co. LP increased its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after buying an additional 739,000 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Kevin R. Sayer sold 32,498 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,657 shares of company stock valued at $8,019,422. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Stock Up 3.2 %

Shares of DXCM opened at $70.69 on Friday. The firm has a market cap of $27.62 billion, a PE ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company’s fifty day moving average is $83.99 and its two-hundred day moving average is $76.85. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.